Phase 3
Completed N=53
Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
Chronic Iron Overload
Source: ClinicalTrials.gov NCT02720536 ↗
Enrolled (actual)
53
Serious AEs
24.5%
Results posted
Mar 2020
Primary outcomePrimary: Overview of Number of Participants With Adverse Events — 52; 20; 14; 2 number of participants
◆ Published Evidence
Emerging
10citations · ~2 / year
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.
Summary
Extend evaluation of deferasirox film-coated tablet (FCT) formulation
Linked Publications
-
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overview of Number of Participants With Adverse Events |
52; 20; 14; 2; 13; 0 | — |
| PRIMARY Change From Baseline Red Blood Cells (RBC) (10^12 Cells/L) at Month 6 and Month 12 |
3.753; 3.733; 3.746; NA; 3.610; 3.607 | — |
| PRIMARY Change From Baseline White Blood Cells (WBC) (10^9 Cells/L) at Month 6 and Month 12 |
9.336; 9.559; 9.100; NA; 9.090; 9.007 | — |
| PRIMARY Change From Baseline Platelets (10^9 Cells/L) at Month 6 and Month 12 |
330.1; 336.5; 339.4; NA; 344.2; 361.9 | — |
| PRIMARY Change From Baseline Serum Creatinine (Umol/L) at Month 6 and Month 12 |
55.1; 54.4; 57.4; NA; 62.0; 63.5 | — |
| PRIMARY Change From Baseline Creatinine Clearance (mL/Min) at Month 6 and Month 12 |
131.9; 131.8; 129.6; NA; 116.0; 119.8 | — |
| PRIMARY Change From Baseline Alanine Aminotransferase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) (U/L) at Month 6 and Month 12 |
37.4; 39.4; 39.5; NA; 28.9; 25.9 | — |
| PRIMARY Change From Baseline Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) (U/L) at Month 6 and Month 12 |
30.7; 32.9; 33.7; NA; 27.6; 25.2 | — |
| SECONDARY Change From Baseline of Serum Ferritin Level (ug/L) at Month 6 and 12 |
2523.51; 2614.12; 2542.76; NA; 2228.94; 1924.49 | — |
| SECONDARY Percentage Relative Change From Baseline of Serum Ferritin (%) at Month 6 and 12 |
NA; -18.61; -29.08 | — |
Eligibility Criteria
Key Inclusion Criteria for subjects:
- Completed 24-weeks of study treatment as described in the core protocol (CICL670F2201).
- Were deemed to have tolerated deferasirox treatment by the investigator.
- Provided written informed consent/assent before any study-specific procedures were performed. For pediatric patients, consent was obtained from parent(s) or legal patient's representative. Investigators were to have also obtained assent of patients according to local, regional or national guidelines.
Key Exclusion for subjects:
The exclusion criteria followed those described for the core protocol CICl670F2201, which were as follows:
- Creatinine clearance below the contraindication limit in the locally approved prescribing information.
- Serum creatinine > 1.5 × upper limit of normal range (ULN) at Screening
- Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) > 5 × ULN,
- Significant proteinuria
- Patients with significant impaired gastrointestinal function or gastrointestinal disease
- Clinical or laboratory evidence of active Hepatitis B or Hepatitis C
- Patients with psychiatric or addictive disorders
- Patients with a known history of HIV seropositivity (Elisa or Western blot).
- History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there was an evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
- Patients with a history of hypersensitivity to any of the study drug or excipients.
- Patients with significant medical condition that could interfere with the ability to participate in this study
- Patients who were participating in another clinical trial or receiving an investigational drug.
- Patients using prohibited medication,
- Patients with liver disease with severity of Child-Pugh Class B or C.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they were using effective methods of contraception during dosing of study treatment
Data sourced from ClinicalTrials.gov (NCT02720536) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.